Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial

Critical Care Medicine

Volumn 32, Issue 2, 2004, Pages 332-341

  Opal, Steven ^a   Laterre, Pierre Francois ^b   Abraham, Edward ^c   Francois, Bruno ^d   Wittebole, Xavier ^b   Lowry, Stephen ^e   Dhainaut, Jean Francois ^f   Warren, Brian ^g   Dugernier, Thierry ^h   Lopez, Angel ⁱ   Sanchez, Miguel ^j   Demeyer, Ignace ^k   Jauregui, Luis ^l   Lorente, Jose Angel ^m   McGee, William ⁿ   Reinhart, Konrad ^o   Kljucar, Sascha ^p   Souza, Sonia ^q   Pribble, John ^q  

^a BROWN UNIVERSITY   (United States)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^c UNIVERSITY OF COLORADO   (United States)

^d DUPUYTREN UNIVERSITY HOSPITAL   (France)

^e ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^f Groupe Hospitalier Cochin ^*  (France)

^g STELLENBOSCH UNIVERSITY   (South Africa)

^h Clinique Saint Pierre of Ottignies   (Belgium)

ⁱ HOSPITAL INFANTA CRISTINA   (Spain)

^j Unidad de Cuidados Intensivos   (Spain)

^k OLV HOSPITAL   (Belgium)

^l ST VINCENT MERCY MEDICAL CENTER   (United States)

^m HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

ⁿ BAYSTATE MEDICAL CENTER   (United States)

^o FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^p DRK KLINIKEN BERLIN WESTEND   (Germany)

^q ELI LILLY AND COMPANY   (United States)

more..

Author keywords

Acute respiratory distress syndrome; Platelet activating factor; Platelet activating factor acetylhydrolase; Sepsis; Septic shock; Severe sepsis

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; PLACEBO;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PATIENT MONITORING; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SEPSIS; SIDE EFFECT; STATISTICAL SIGNIFICANCE;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; SEPSIS; SEVERITY OF ILLNESS INDEX;

EID: 10744219506     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000108867.87890.6D     Document Type: Article

References (51)

1. Lorant DE, Zimmerman GA, McIntyre TM, et al: Platelet-activating factor mediates procoagulant activity on the surface of endothelial cells by promoting leukocyte adhesion. Semin Cell Biol 1995; 6:295-303
2. Ostrovsky L, King AJ, Bond S, et al: A juxtacrine mechanism for neutrophil adhesion on platelets involves platelet-activating factor and a selectin-dependent activation process. Blood 1998; 91:3028-3036
3. Imaizumi TA, Stafforini DM, Yamada Y, et al: Platelet-activating factor: A mediator for clinicians. J Intern Med 1995; 238:5-20
4. Mathiak G, Szewczyk D, Abdullah F, et al: Platelet-activating factor (PAF) in experimental and clinical sepsis. Shock 1997; 7:391-404
5. Coughlan AF, Hau H, Dunlop LC, et al: P-selectin and platelet-activating factor mediate initial endotoxin-induced neutropenia. J Exp Med 1994; 179:329-334
6. Szabo C, Wu CC, Mitchell JA, et al: Platelet-activating factor contributes to the induction of nitric oxide synthase by bacterial lipopolysaccharide. Circ Res 1993; 73:991-999
7. Bussolino F, Porcellini MG, Varese L, et al: Intravascular release of platelet activating factor in children with sepsis. Thromb Res 1987; 48:619-620
8. Lopez Diez F, Nieto ML, Fernandez-Gallardo S, et al: Occupancy of platelet receptors for platelet-activating factor in patients with septicemia. J Clin Invest 1989; 83:1733-1740
9. Heuer HO: Involvement of platelet-activating factor (PAF) in septic shock and priming as indicated by the effect of hetrazepinoic PAF antagonists. Lipids 1991; 26:1369-1373
10. Zimmerman GA, McIntyre TM, Prescott SM, et al: The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis. Crit Care Med 2002; 30:S294-S301
11. Prescott S, McIntyre T, Zimmerman G: Two of the usual suspects, platelet-activating factor and its receptor, implicated in acute lung injury. J Clin Invest 1999; 104:1019-1020
12. Stafforini DM, McIntyre TM, Zimmerman GA, et al: Platelet-activating factor acetylhydrolases. J Biol Chem 1997; 272:17895-17898
13. Mikita T, Porter G, Lawn RM, et al: Oxidized low density lipoprotein exposure alters the transcriptional response to inflammatory stimulus. J Biol Chem 2001; 276:45729-45739
14. Xu XH, Shaw PK, Faure E, et al: Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plagues and upregulated by oxidized LDL. Circulation 2001; 104:3103-3108
15. Fan J, Kapus A, Marsden PA, et al: Regulation of Toll-like receptor 4 expression in the lung following hemorrhagic shock and lipopolysaccharide. J Immunol 2002; 168:5252-5259
16. Henson P, Barnes P, Banks-Schlegel S: Platelet-activating factor: Role in pulmonary injury and dysfunction and blood abnormalities. Am Rev Respir Dis 1992; 145:726-731
17. Matsumoto K, Takki F, Kondoh Y, et al: Platelet-activating factor in bronchoalveolar lavage fluid of patients with adult respiratory distress syndrome. Clin Exper Pharm Physiol 1992; 19:509-515
18. 2 in subjects with septic shock and trauma. Intensive Care Med 1994; 20:555-561
19. Ishii S, Nagase T, Tashiro F, et al: Bronchial hyper-reactivity, increased endotoxin lethality and melanocytic tumorigenesis in transgenic mice overexpressing platelet-activating factor receptor. Embo J 1997; 16:133-142
20. Siebeck M, Weipert J, Kesser C, et al: A triazolodiasepine platelet activating factor receptor antagonist (WEB 2086) reduces pulmonary dysfunction during endotoxin shock in swine. J Trauma 1991; 31:942-950
21. Olsen N, Joyce P, Fleisher L: Role of platelet-activating factor and eicosanoids during endotoxin-induced lung injuries in pigs. J Am Physiol 1990; 258:H1674-H1686
22. Christman B, Lefferts P, Blair I, et al: Effect of platelet-activating factor receptor antagonism on endotoxin-induced lung dysfunction in awake sheep. Am Rev Respir Dis 1990; 142:1272-1278
23. Thompson WA, Coyle S, Van Zee K, et al: The metabolic effects of platelet-activating factor antagonism in endotoxemic man. Arch Surg 1994; 129:72-79
24. Poeze M, Froon A, Ramsay G, et al: Decreased organ failure in patients with severe SIRS and septic shock treated with the platelet-activating factor antagonist TCV-309: A prospective, multicenter, double-blind, randomized phase II trial. Shock 2000; 14:421-428
25. Vincent J, Spapen H, Bakker J, et al: Phase II multicenter clinical study of the platelet-activating factor receptor antagonist BB-882 in the treatment of sepsis. Crit Care Med 2000; 28:638-642
26. Dhainaut J, Tenaillon A, Hemmer M, et al: Confirmatory platelet-activating factor receptor antagonist trial in patients with severe Gram-negative bacterial sepsis: A phase III, randomized, double-blind, placebo-controlled, multicenter trial. Crit Care Med 1998; 26:1963-1971
27. Tjoelker L, Wilder C, Eberhardt C, et al: Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature 1995; 374:549-552
28. Zygmunt S, Derewenda Y, Ho YS: PAF-acetylhydrolases. Biochimica Biophysica Acta 1999; 229-236
29. Graham RM, Stephens CJ, Silvester W, et al: Plasma degradation of platelet-activating factor in severely ill patients with clinical sepsis. Crit Care Med 1994; 22:204-212
30. Marathe GK, Harrison KA, Murphy RC, et al: Bioactive phospholipid oxidation products. Free Radic Biol Med 2000; 28:1762-1770
31. Partrick D, Moore E, Moore F, et al: Reduced PAF-acetylhydrolase activity is associated with post-injury multiple organ failure. Shock 1997; 7:170-174
32. Cao Y, Stafforini DM, Zimmerman GA, et al: Expression of plasma platelet-activating factor acetylhydrolase is transcriptionally regulated by mediators of inflammation. J Biol Chem 1998; 273:4012-4020
33. Prescott SM, Zimmerman GA, Stafforini DM, et al: Platelet-activating factor and related lipid mediators. Annu Rev Biochem 2000; 69:419-445
34. Horkheimer I, Schuster DP: The role of platelet-activating factor in sepsis: A bench-to-bedside review. Adv Sepsis 2002; 2:2-7
35. Hofbauer B, Saluja AK, Bhatia M, et al: Effect of recombinant platelet-activating factor acetylhydrolase on two models of experimental acute pancreatitis. Gastroenterol 1998; 115:1238-1247
36. Schuster DP, Metzler M, Opal SM, et al: Recombinant platelet-activating factor acetylhydrolase to prevent acute respiratory distress syndrome and mortality in severe sepsis: Phase IIb, multicenter, randomized, placebo-controlled, clinical trial. Crit Care Med 2003; 31:1612-1619
37. Knaus W, Draper E, Wagner D, et al: APACHE II: A severity of disease classification system. Crit Care Med 1985; 13:818-829
38. Marshall J, Cook D, Christou N, et al: Multiple organ dysfunction score: A reliable descriptor of a complex clinical outcome. Crit Care Med 1995; 23:1638-1652
39. Bernard GR, Artigas A, Grigham KL, et al: The American-European consensus conference on ARDS: Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994; 149:818-824
40. Emerson SS, Flemming TR: Symmetric group sequential designs. Biometrics 1989; 45:905-923
41. Warren BL, Eid A, Singer P, et al: High-dose antithrombin III in severe sepsis. JAMA 2001; 286:1869-1887
42. Opal SM, Fisher CJ, Pribble JP, et al: The confirmatory interleukin-1 receptor antagonist trial in sepsis: A phase III randomized, double-blind, placebo-controlled, multicenter trial. Crit Care Med 1997; 25:1115-1123
43. DePalo V, Kessler C, Opal SM: Success or failure in phase 3 sepsis trials: Comparison of the activated protein C and antithrombin clinical trials. Adv Sepsis 2001; 1:114-125
44. Opal SM, Cross AS: Clinical trials for sepsis: Past failures and future hopes. Infect Dis Clin North Am 1999; 13:285-298
45. Abraham E, Matthay MA, Dinarello CA, et al: Consensus conference definitions for sepsis, acute lung injury, and ARDS: Time for reevaluation. Crit Care Med 2000; 28:232-236
46. Hotchkiss RS, Karl IE: Medical progress: The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348:138-150
47. Bratton DL, Dreyer E, Kailey JM, et al: The mechanism of internalization of platelet-activating factor in activated human neutrophils. Crit Care Med 1992; 148:514-523
48. 2+] in human airway epithelial cells. J Biol Chem 1994; 269: 4254-4259
49. Lindemann S, Tolley ND, Dixon DA, et al: Activated platelets mediate inflammatory signaling by regulated interleukin-1beta synthesis. J Cell Biol 2001; 154:485-490
50. US Food and Drug Administration: FDA clinical review drotrecogin alfa (activated). Available online at http://www.fda.gov/cber/review/droteli112101r1. pdf. Accessed May 27, 2003.
51. Natanson C, Esposito CJ, Banks SM: The sirens' songs of confirmatory sepsis trials: Selection bias and sampling error. Crit Care Med 1998; 26:1927-1931